Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Perennial Allergic Rhinitis Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Perennial Allergic Rhinitis Overview | 7 | 1 |
| Pipeline Products for Perennial Allergic Rhinitis Comparative Analysis | 8 | 1 |
| Perennial Allergic Rhinitis Therapeutics under Development by Companies | 9 | 1 |
| Perennial Allergic Rhinitis Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Perennial Allergic Rhinitis Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Perennial Allergic Rhinitis Products under Development by Companies | 13 | 1 |
| Perennial Allergic Rhinitis Products under Investigation by Universities/Institutes | 14 | 1 |
| Perennial Allergic Rhinitis Companies Involved in Therapeutics Development | 15 | 8 |
| Faes Farma, S.A. | 16 | 1 |
| Glenmark Pharmaceuticals Ltd. | 17 | 1 |
| Hisamitsu Pharmaceutical Co., Inc. | 18 | 1 |
| Merck &Co., Inc. | 19 | 1 |
| Pfizer Inc. | 20 | 1 |
| Shionogi &Co., Ltd. | 21 | 1 |
| VentiRx Pharmaceuticals, Inc. | 22 | 1 |
| Perennial Allergic Rhinitis Therapeutics Assessment | 23 | 10 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Combination Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 14 |
| (levocabastine hydrochloride + mometasone furoate) Drug Profile | 33 | 1 |
| Allergen for Asthma and Perennial Allergic Rhinitis Drug Profile | 34 | 1 |
| asapiprant Drug Profile | 35 | 1 |
| bilastine Drug Profile | 36 | 2 |
| desloratadine Drug Profile | 38 | 2 |
| emedastine difumarate Drug Profile | 40 | 1 |
| GSP-301 Drug Profile | 41 | 1 |
| PF-06444752 Drug Profile | 42 | 2 |
| PF-06444753 Drug Profile | 44 | 2 |
| VTX-1463 Drug Profile | 46 | 1 |
| Perennial Allergic Rhinitis Dormant Projects | 47 | 1 |
| Perennial Allergic Rhinitis Discontinued Products | 48 | 1 |
| Perennial Allergic Rhinitis Product Development Milestones | 49 | 1 |
| Featured News &Press Releases | 49 | 1 |
| Aug 13, 2015: PENDOPHARM announces Nasacort Allergy 24H Nasal Spray is now available without a prescription in Canadian Province | 49 | 1 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |